

## Descriptions of Additional Supplementary Files

### Supplementary Data 1

**Description:** Supplementary Data 1a Differentially expressed genes between inflamed biopsies and non-inflamed biopsies (linear regression, two-sided t-test,  $FDR < 0.001$ ,  $|\beta| > 1.5$ ); Supplementary Data 1b, REACTOME top annotations for genes differentially expressed between inflamed and non-inflamed tissues (P values were obtained from two-sided Wilcoxon test).

### Supplementary Data 2

**Description:** Supplementary Data 2a Differentially expressed genes between CD and UC (linear regression, two-sided t-test,  $FDR < 0.001$ ,  $|\beta| > 1.5$ ); Supplementary Data 2b, REACTOME top annotations for genes differentially expressed between CD and UC (P values were obtained from two-sided Wilcoxon test).

### Supplementary Data 3

#### Description:

Supplementary Data 3a Differentially expressed genes between colon and ileum (linear regression, two-sided t-test,  $FDR < 0.001$ ,  $|\beta| > 1.5$ ); Supplementary Data 3b, REACTOME top annotations for genes differentially expressed between colon and ileum (P values were obtained from two-sided Wilcoxon test).

### Supplementary Data 4

**Description:** Supplementary Data 4a 8,881 unique *cis*-eQTL pairs (linear regression, two-sided t-test,  $FDR < 0.05$ ); Supplementary Data 4b Replication of 39 out of 47 RISK *cis*-eQTLs (Marigorta, UM, et, al (2017). Nature Genetics, 49 (10), 1517.); Supplementary Data 4c Q test of six eQTLs in this study with different directions of effect compared with three GTEx datasets (Cochran-Q test).

### Supplementary Data 5

**Description:** Supplementary Data 5a *cis*-eQTLs colocalized with IBD GWAS (De Lange, KM, et, al (2017). Nature Genetics, 49 (2), 256-261.); Supplementary Data 5b *cis*-eQTLs colocalized with CD GWAS (De Lange, KM, et, al (2017). Nature Genetics, 49 (2), 256-261.); Supplementary Data 5c *cis*-eQTLs colocalized with UC GWAS (De Lange, KM, et, al (2017). Nature Genetics, 49 (2), 256-261.); Supplementary Data 5d *cis*-eQTLs colocalized with colon cancer GWAS (ukb-b-16890); Supplementary Data 5e *cis*-eQTLs colocalized with diverticulitis GWAS (ukb-b-14796); Supplementary Data 5f *cis*-eQTLs colocalized with coeliac GWAS (ukb-b-8631).

### Supplementary Data 6

**Description:** Supplementary Data 6a 190 inflammation-dependent *cis*-eQTLs after multiple testing correction (linear regression, two-sided t-test,  $FDR < 0.05$ ).; Supplementary Data 6b Full summary statistics for 190 inflammation-dependent *cis*-eQTLs after multiple testing correction (linear regression, two-sided t-test,  $FDR < 0.05$ ).

### Supplementary Data 7

**Description:** REACTOME annotations of 190 inflammation-dependent *cis*-eQTLs (P values were obtained from two-sided Wilcoxon test).

### **Supplementary Data 8**

**Description:** 2,466 co-expressed genes amongst 190 inflammation-dependent eGenes (Spearman correlation,  $|r| > 0.5$ , FDR < 0.05)

### **Supplementary Data 9**

Supplementary Data 9 125 inflammation-dependent *cis*-eQTLs interacting with celltype enrichment (linear regression, two-sided t-test, FDR interaction <0.05).

### **Supplementary Data 10**

Supplementary Data 10a Annotation regulatory features of intestinal eQTLs at Haploreg;  
Supplementary Data 10b Annotation regulatory features of inflammation-dependent eQTLs at Haploreg (P values were obtained from Chi-square tests).

### **Supplementary Data 11**

Supplementary Data 11 Drug Targets overlapping with Inflammation-dependent eQTLs (sources: Open Targets and DrugBank).